Home Current issue Ahead of print Search About us Editorial board Archives Submit article Instructions Subscribe Contacts Login 
Year : 2019  |  Volume : 38  |  Issue : 3  |  Page : 429-438

Survival of primary adenocarcinoma of the urinary bladder after radical treatment: National Cancer Institute, 5-years’ experience

1 Department of Surgical Oncology, National Cancer Institute, Cairo University, Cairo, Egypt
2 Department of Pathology, National Cancer Institute, Cairo University, Cairo, Egypt

Correspondence Address:
Ahmed Abbas
Surgical Oncology Department, National Cancer Institute, Cairo University
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/ejs.ejs_18_19

Rights and Permissions

Introduction Primary adenocarcinoma of the urinary bladder (UB) is rare but often aggressive urologic cancer. It represents 0.5–2% of all bladder cancers and affects patients mostly in their sixth decade of life. The incidence is greater in areas where bilharziasis is endemic and is more common in men than women. Aim of the work The aim of the study was to review this rare UB malignancy with special emphasis on patients’ survival including; disease-free survival (DFS) and overall survival (OS) in relation to different clinical and pathological factors. Patients and methods We conducted this retrospective review of 40 patients with primary UB adenocarcinoma who were treated and followed up in the National Cancer Institute, Cairo University between January 2013 and December 2017. Results The study included 40 patients with a male to female ratio of 82.5 : 17.5%. The mean age at diagnosis was 61 years. Hematuria was the most common presenting symptom followed by dysuria and frequency. Pathologically, stage III disease, tumor grade II, and adenocarcinoma, not otherwise specified, were the most common findings. Radical cystectomy was done in 82.5% of cases, while anterior pelvic exenteration was done in 17.55% of cases followed in both by different methods of urinary diversions. The median follow-up was 31 months, and the 2-year DFS of all patients was 60.7%. Two-year DFS was significantly affected by tumor grade, disease stage, and lymph node (LN) status (P=0.019, 0.021, 0.001, respectively). Furthermore, 3-year OS of all groups was 57% with a median follow-up of 39.9 month. Tumor grade, disease stage, and LN involvement had an impact on OS. However, the only statistically significant effect is due to LN involvement (P=0.037). Conclusion Patients with UB adenocarcinoma commonly present in an advanced disease. DFS and OS are affected by disease stage, tumor grade, and LN involvement. We recommend radical rather than any form of conservative surgery as a primary treatment modality.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded22    
    Comments [Add]    

Recommend this journal